Diversity of KIR genes and their HLA-C ligands in Ugandan populations with historically varied malaria transmission intensity.
Genetic diversity
Human leukocyte antigen
Killer-cell immunoglobulin-like receptor
Malaria
Uganda
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
25 Feb 2021
25 Feb 2021
Historique:
received:
22
07
2020
accepted:
16
02
2021
entrez:
26
2
2021
pubmed:
27
2
2021
medline:
14
8
2021
Statut:
epublish
Résumé
Malaria is one of the most serious infectious diseases in the world. The malaria burden is greatly affected by human immunity, and immune responses vary between populations. Genetic diversity in KIR and HLA-C genes, which are important in immunity to infectious diseases, is likely to play a role in this heterogeneity. Several studies have shown that KIR and HLA-C genes influence the immune response to viral infections, but few studies have examined the role of KIR and HLA-C in malaria infection, and these have used low-resolution genotyping. The aim of this study was to determine whether genetic variation in KIR and their HLA-C ligands differ in Ugandan populations with historically varied malaria transmission intensity using more comprehensive genotyping approaches. High throughput multiplex quantitative real-time PCR method was used to genotype KIR genetic variants and copy number variation and a high-throughput real-time PCR method was developed to genotype HLA-C1 and C2 allotypes for 1344 participants, aged 6 months to 10 years, enrolled from Ugandan populations with historically high (Tororo District), medium (Jinja District) and low (Kanungu District) malaria transmission intensity. The prevalence of KIR3DS1, KIR2DL5, KIR2DS5, and KIR2DS1 genes was significantly lower in populations from Kanungu compared to Tororo (7.6 vs 13.2%: p = 0.006, 57.2 vs 66.4%: p = 0.005, 33.2 vs 46.6%: p < 0.001, and 19.7 vs 26.7%: p = 0.014, respectively) or Jinja (7.6 vs 18.1%: p < 0.001, 57.2 vs 63.8%: p = 0.048, 33.2 vs 43.5%: p = 0.002, and 19.7 vs 30.4%: p < 0.001, respectively). The prevalence of homozygous HLA-C2 was significantly higher in populations from Kanungu (31.6%) compared to Jinja (21.4%), p = 0.043, with no significant difference between Kanungu and Tororo (26.7%), p = 0.296. The KIR3DS1, KIR2DL5, KIR2DS5 and KIR2DS1 genes may partly explain differences in transmission intensity of malaria since these genes have been positively selected for in places with historically high malaria transmission intensity. The high-throughput, multiplex, real-time HLA-C genotyping PCR method developed will be useful in disease-association studies involving large cohorts.
Sections du résumé
BACKGROUND
BACKGROUND
Malaria is one of the most serious infectious diseases in the world. The malaria burden is greatly affected by human immunity, and immune responses vary between populations. Genetic diversity in KIR and HLA-C genes, which are important in immunity to infectious diseases, is likely to play a role in this heterogeneity. Several studies have shown that KIR and HLA-C genes influence the immune response to viral infections, but few studies have examined the role of KIR and HLA-C in malaria infection, and these have used low-resolution genotyping. The aim of this study was to determine whether genetic variation in KIR and their HLA-C ligands differ in Ugandan populations with historically varied malaria transmission intensity using more comprehensive genotyping approaches.
METHODS
METHODS
High throughput multiplex quantitative real-time PCR method was used to genotype KIR genetic variants and copy number variation and a high-throughput real-time PCR method was developed to genotype HLA-C1 and C2 allotypes for 1344 participants, aged 6 months to 10 years, enrolled from Ugandan populations with historically high (Tororo District), medium (Jinja District) and low (Kanungu District) malaria transmission intensity.
RESULTS
RESULTS
The prevalence of KIR3DS1, KIR2DL5, KIR2DS5, and KIR2DS1 genes was significantly lower in populations from Kanungu compared to Tororo (7.6 vs 13.2%: p = 0.006, 57.2 vs 66.4%: p = 0.005, 33.2 vs 46.6%: p < 0.001, and 19.7 vs 26.7%: p = 0.014, respectively) or Jinja (7.6 vs 18.1%: p < 0.001, 57.2 vs 63.8%: p = 0.048, 33.2 vs 43.5%: p = 0.002, and 19.7 vs 30.4%: p < 0.001, respectively). The prevalence of homozygous HLA-C2 was significantly higher in populations from Kanungu (31.6%) compared to Jinja (21.4%), p = 0.043, with no significant difference between Kanungu and Tororo (26.7%), p = 0.296.
CONCLUSIONS
CONCLUSIONS
The KIR3DS1, KIR2DL5, KIR2DS5 and KIR2DS1 genes may partly explain differences in transmission intensity of malaria since these genes have been positively selected for in places with historically high malaria transmission intensity. The high-throughput, multiplex, real-time HLA-C genotyping PCR method developed will be useful in disease-association studies involving large cohorts.
Identifiants
pubmed: 33632228
doi: 10.1186/s12936-021-03652-y
pii: 10.1186/s12936-021-03652-y
pmc: PMC7908804
doi:
Substances chimiques
HLA-C Antigens
0
Ligands
0
Potassium Channels, Inwardly Rectifying
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111Subventions
Organisme : NIH HHS
ID : AI089674
Pays : United States
Organisme : NIH HHS
ID : TW007375
Pays : United States
Organisme : This work was supported through the DELTAS Africa Initiative
ID : Grant no. 107743
Organisme : NIH HHS
ID : AI075045
Pays : United States
Organisme : European Research Council
ID : 695551
Pays : International
Organisme : NIAID NIH HHS
ID : U19 AI089674
Pays : United States
Organisme : Wellcome Trust
ID : 200841/Z/16/Z
Pays : United Kingdom
Organisme : NIH HHS
ID : TW009343
Pays : United States
Organisme : Fogarty International Center of the National Institutes of Health
ID : D43TW010526
Organisme : Fogarty International Center, Emerging Global Leader Award
ID : K43TW010365
Références
Cell Mol Immunol. 2020 Aug;17(8):799-806
pubmed: 32541835
Gene. 2010 Nov 1;467(1-2):1-12
pubmed: 20655368
PLoS Genet. 2013 Oct;9(10):e1003938
pubmed: 24204327
J Exp Med. 2005 Apr 4;201(7):1069-75
pubmed: 15809352
J Leukoc Biol. 2011 Oct;90(4):703-16
pubmed: 21873457
Malar J. 2016 Sep 15;15:470
pubmed: 27628178
J Exp Med. 1995 Aug 1;182(2):605-9
pubmed: 7629517
Blood. 2013 Jun 6;121(23):4703-7
pubmed: 23637128
Front Immunol. 2012 Nov 01;3:326
pubmed: 23125843
Semin Immunol. 2008 Dec;20(6):343-52
pubmed: 18635379
Immunogenetics. 2013 Nov;65(11):765-75
pubmed: 23974321
J Vis Exp. 2019 Mar 6;(145):
pubmed: 30907867
PLoS Pathog. 2011 Dec;7(12):e1002436
pubmed: 22194686
Hum Immunol. 2014 Aug;75(8):816-21
pubmed: 24929143
Science. 2004 Aug 6;305(5685):872-4
pubmed: 15297676
Trends Genet. 2020 Apr;36(4):298-311
pubmed: 32044115
PLoS Med. 2016 Nov 8;13(11):e1002167
pubmed: 27824885
PLoS One. 2012;7(10):e47463
pubmed: 23144702
Front Immunol. 2017 Mar 09;8:212
pubmed: 28337195
PLoS Biol. 2011 Nov;9(11):e1001208
pubmed: 22140359
J Immunol. 2019 May 1;202(9):2636-2647
pubmed: 30918042
Front Immunol. 2019 May 28;10:1179
pubmed: 31231370
PLoS One. 2012;7(9):e43987
pubmed: 22957039
Br J Haematol. 2008 May;141(3):276-86
pubmed: 18410566
J Exp Med. 2004 Oct 18;200(8):957-65
pubmed: 15477349
PLoS Pathog. 2012;8(3):e1002565
pubmed: 22412373
Clin Microbiol Rev. 2009 Jan;22(1):13-36, Table of Contents
pubmed: 19136431
Acta Trop. 2012 Mar;121(3):184-95
pubmed: 21420377
Nat Commun. 2019 Dec 16;10(1):5732
pubmed: 31844061
Immunity. 2011 Nov 23;35(5):653-7
pubmed: 22118518
Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):845-50
pubmed: 25561558
Immunol Rev. 2006 Dec;214:186-201
pubmed: 17100885
Genome Med. 2016 Sep 29;8(1):99
pubmed: 27686127
Am J Trop Med Hyg. 2015 May;92(5):903-12
pubmed: 25778501
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Nat Genet. 2007 Sep;39(9):1092-9
pubmed: 17694054
Clin Microbiol Rev. 2002 Oct;15(4):564-94
pubmed: 12364370
J Immunol. 2008 Mar 15;180(6):3969-79
pubmed: 18322206
Nat Rev Immunol. 2005 Mar;5(3):201-14
pubmed: 15719024
Infect Genet Evol. 2017 Nov;55:281-287
pubmed: 28939159
Genome Res. 2009 May;19(5):757-69
pubmed: 19411600
Am J Hum Genet. 2005 Aug;77(2):171-92
pubmed: 16001361
Immunogenetics. 2018 Jan;70(1):5-27
pubmed: 28687858
Heredity (Edinb). 2011 Oct;107(4):283-304
pubmed: 21427751
Malar J. 2019 Sep 18;18(1):321
pubmed: 31533835